Phase III results for CSL Seqirus' MF59-adjuvanted flu vaccine

New peer-reviewed data published in The Lancet Infectious Diseases report results from a Phase III study of 7,699 adults aged 50+ across eight countries, evaluating Australia’s CSL Ltd’s (ASX: CSL) subsidiary CSL Seqirus' MF59-adjuvanted, cell-based, higher-dose quadrivalent influenza vaccine (aQIVc). aQIVc is the quadrivalent formulation of the trivalent vaccine aTIVc, and the findings of this study extrapolate to the trivalent formulation.

The study found that aQIVc demonstrated superior immunogenicity over a standard-dose aQIV vaccine for all four influenza strains, with antibody levels 22% to 73% higher with aQIVc than with aQIV. The proportion of participants achieving levels that are generally considered immunoprotective were 9.5 to 24.3 percentage points higher.